Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2013 | -485.67 Thousand USD | 20.2% |
| 2012 | -1.2 Million USD | 42.1% |
| 2011 | -1 Million USD | 78.11% |
| 2010 | 58.59 Thousand USD | -12.22% |
| 2009 | -8.18 Million USD | 55.56% |
| 2008 | -18.57 Million USD | 0.32% |
| 2007 | -18.58 Million USD | 28.87% |
| 2006 | -26.08 Million USD | -131.12% |
| 2005 | -11.24 Million USD | -12.5% |
| 2004 | -10.02 Million USD | -32.14% |
| 2003 | -7.69 Million USD | 16.57% |
| 2002 | -9.21 Million USD | 6.33% |
| 2001 | -9.84 Million USD | 13.88% |
| 2000 | -11.42 Million USD | -3.9% |
| 1999 | -11 Million USD | -32.53% |
| 1998 | -7.6 Million USD | 17.82% |
| 1997 | -9 Million USD | -158.97% |
| 1996 | -6.5 Million USD | -145.88% |
| 1995 | -1.8 Million USD | 206.25% |
| 1994 | -8 Million USD | 62.26% |
| 1993 | -21.2 Million USD | -45.21% |
| 1992 | -14.6 Million USD | -15.87% |
| 1991 | -12.6 Million USD | -41.57% |
| 1990 | -8.9 Million USD | -1.14% |
| 1989 | -8.8 Million USD | 32.31% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2014 Q1 | -329.72 Thousand USD | -193.85% |
| 2014 Q2 | -316.2 Thousand USD | 4.1% |
| 2013 Q2 | -352.49 Thousand USD | 16.09% |
| 2013 Q4 | 351.34 Thousand USD | 201.63% |
| 2013 FY | - USD | 20.2% |
| 2013 Q3 | -345.72 Thousand USD | 1.92% |
| 2013 Q1 | -420.06 Thousand USD | -32.26% |
| 2012 Q2 | -188.86 Thousand USD | 13.14% |
| 2012 Q4 | -317.6 Thousand USD | 30.97% |
| 2012 FY | - USD | 42.1% |
| 2012 Q1 | -217.42 Thousand USD | -127.13% |
| 2012 Q3 | -460.1 Thousand USD | -143.62% |
| 2011 FY | - USD | 78.11% |
| 2011 Q2 | -1.17 Million USD | -93.08% |
| 2011 Q4 | 801.37 Thousand USD | 175.63% |
| 2011 Q3 | -1.05 Million USD | 10.0% |
| 2011 Q1 | -609.75 Thousand USD | -188.59% |
| 2010 Q3 | -6.99 Million USD | -638.72% |
| 2010 Q4 | -211.28 Thousand USD | 96.98% |
| 2010 Q1 | -1.18 Million USD | -7.7% |
| 2010 Q2 | -947.19 Thousand USD | 20.12% |
| 2010 FY | - USD | -12.22% |
| 2009 Q2 | -1.96 Million USD | 48.87% |
| 2009 FY | - USD | 55.56% |
| 2009 Q4 | -1.1 Million USD | 21.94% |
| 2009 Q1 | -3.84 Million USD | -4.45% |
| 2009 Q3 | -1.41 Million USD | 28.3% |
| 2008 Q2 | -5.59 Million USD | -13.48% |
| 2008 Q1 | -4.92 Million USD | 2.88% |
| 2008 FY | - USD | 0.32% |
| 2008 Q4 | -3.68 Million USD | 18.69% |
| 2008 Q3 | -4.52 Million USD | 19.03% |
| 2007 FY | - USD | 28.87% |
| 2007 Q4 | -5.07 Million USD | -12.21% |
| 2007 Q1 | -4.16 Million USD | 71.04% |
| 2007 Q2 | -5.15 Million USD | -23.9% |
| 2007 Q3 | -4.52 Million USD | 12.29% |
| 2006 Q1 | -4.07 Million USD | -26.81% |
| 2006 FY | - USD | -131.12% |
| 2006 Q3 | -4 Million USD | -1.11% |
| 2006 Q2 | -3.96 Million USD | 2.79% |
| 2006 Q4 | -14.37 Million USD | -258.61% |
| 2005 Q2 | -2.37 Million USD | -5.46% |
| 2005 Q1 | -2.25 Million USD | -47.48% |
| 2005 FY | - USD | -12.5% |
| 2005 Q3 | -3.72 Million USD | -56.66% |
| 2005 Q4 | -3.21 Million USD | 13.72% |
| 2004 Q2 | -3.83 Million USD | -52.51% |
| 2004 Q4 | -1.52 Million USD | 35.04% |
| 2004 Q3 | -2.35 Million USD | 38.57% |
| 2004 Q1 | -2.51 Million USD | -42.0% |
| 2004 FY | - USD | -32.14% |
| 2003 Q2 | -1.81 Million USD | 13.4% |
| 2003 Q4 | -1.76 Million USD | 6.31% |
| 2003 Q3 | -1.83 Million USD | 4.02% |
| 2003 FY | - USD | 16.57% |
| 2003 Q1 | -2.27 Million USD | -46.73% |
| 2002 FY | - USD | 6.33% |
| 2002 Q4 | -2.15 Million USD | 37.15% |
| 2002 Q1 | -2.94 Million USD | -48.99% |
| 2002 Q2 | -2.55 Million USD | 18.14% |
| 2002 Q3 | -2.46 Million USD | -2.34% |
| 2001 Q3 | -2.71 Million USD | -0.12% |
| 2001 Q4 | -2.26 Million USD | 27.39% |
| 2001 FY | - USD | 13.88% |
| 2001 Q1 | -2.43 Million USD | -31.16% |
| 2001 Q2 | -3.11 Million USD | -11.57% |
| 2000 Q4 | -1.85 Million USD | 43.71% |
| 2000 Q2 | -3.57 Million USD | -42.85% |
| 2000 Q1 | -2.6 Million USD | 60.28% |
| 2000 FY | - USD | -3.9% |
| 2000 Q3 | -3.29 Million USD | 7.79% |
| 1999 Q3 | -600 Thousand USD | 68.42% |
| 1999 FY | - USD | -32.53% |
| 1999 Q4 | -6.3 Million USD | -950.0% |
| 1999 Q2 | -1.9 Million USD | 13.64% |
| 1999 Q1 | -2.2 Million USD | 4.35% |
| 1998 FY | - USD | 17.82% |
| 1998 Q3 | -1.9 Million USD | 5.0% |
| 1998 Q1 | -1.9 Million USD | 26.92% |
| 1998 Q4 | -2.3 Million USD | -21.05% |
| 1998 Q2 | -2 Million USD | -5.26% |
| 1997 Q1 | -2.3 Million USD | -221.05% |
| 1997 FY | - USD | -158.97% |
| 1997 Q4 | -2.6 Million USD | -4.0% |
| 1997 Q3 | -2.5 Million USD | 7.41% |
| 1997 Q2 | -2.7 Million USD | -17.39% |
| 1996 Q2 | -1.9 Million USD | -58.33% |
| 1996 FY | - USD | -145.88% |
| 1996 Q4 | 1.9 Million USD | 182.61% |
| 1996 Q3 | -1.7 Million USD | -21.05% |
| 1996 Q1 | -1.2 Million USD | -111.88% |
| 1995 Q3 | -600 Thousand USD | 94.44% |
| 1995 Q1 | -500 Thousand USD | 0.0% |
| 1995 FY | - USD | 206.25% |
| 1995 Q4 | 10.1 Million USD | 1783.33% |
| 1995 Q2 | -10.8 Million USD | -2060.0% |
| 1994 Q2 | -3.3 Million USD | 13.16% |
| 1994 Q1 | -3.8 Million USD | 48.65% |
| 1994 Q4 | -500 Thousand USD | 16.67% |
| 1994 Q3 | -600 Thousand USD | 81.82% |
| 1994 FY | - USD | 62.26% |
| 1993 Q3 | -4.2 Million USD | -5.0% |
| 1993 Q1 | -5.4 Million USD | -35.0% |
| 1993 FY | - USD | -45.21% |
| 1993 Q4 | -7.4 Million USD | -76.19% |
| 1993 Q2 | -4 Million USD | 25.93% |
| 1992 Q2 | -2.9 Million USD | 0.0% |
| 1992 Q4 | -4 Million USD | 16.67% |
| 1992 Q3 | -4.8 Million USD | -54.84% |
| 1992 Q1 | -3.1 Million USD | 13.89% |
| 1992 FY | - USD | -15.87% |
| 1991 Q1 | -3 Million USD | 79.02% |
| 1991 Q3 | -2.7 Million USD | -325.0% |
| 1991 Q2 | 1.2 Million USD | 140.0% |
| 1991 FY | - USD | -31.25% |
| 1991 Q4 | -3.6 Million USD | -33.33% |
| 1990 Q4 | -14.3 Million USD | -1200.0% |
| 1990 Q2 | 3.7 Million USD | 3600.0% |
| 1990 Q1 | 100 Thousand USD | 100.9% |
| 1990 Q3 | 1.3 Million USD | -64.86% |
| 1990 FY | - USD | -5.49% |
| 1989 FY | - USD | 30.0% |
| 1989 Q3 | 1.1 Million USD | 10.0% |
| 1989 Q1 | 100 Thousand USD | 100.75% |
| 1989 Q2 | 1 Million USD | 900.0% |
| 1989 Q4 | -11.1 Million USD | -1109.09% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.316% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 91.808% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.243% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 97.204% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.516% |
| Mesoblast Limited | -62.38 Million USD | 99.222% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 68.381% |
| Genus plc | 73.7 Million USD | 100.659% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 92.654% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 86.307% |
| Marizyme, Inc. | -34.28 Million USD | 98.583% |
| ContraFect Corporation | -64.99 Million USD | 99.253% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 94.463% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 89.27% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 65.353% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 81.634% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 79.1% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 6.248% |
| Accustem Sciences Inc. | -3.74 Million USD | 87.036% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 98.993% |
| EV Biologics, Inc. | -1.26 Million USD | 61.671% |
| Q BioMed Inc. | -617.62 Thousand USD | 21.364% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 113.597% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 23.202% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 78.74% |
| Biomind Labs Inc. | -1.03 Million USD | 53.054% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 104.917% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 93.218% |
| Skye Bioscience, Inc. | -13.54 Million USD | 96.415% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 67.347% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -1842.712% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 87.496% |
| IMV Inc. | -35.52 Million USD | 98.633% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 96.94% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 80.588% |
| GB Sciences, Inc. | -1.41 Million USD | 65.795% |
| Alpha Cognition Inc. | -9.7 Million USD | 94.996% |
| HST Global, Inc. | -5303.00 USD | -9058.552% |
| CSL Limited | 4.78 Billion USD | 100.01% |
| Halberd Corporation | -74.27 Thousand USD | -553.856% |
| Enzolytics Inc. | -2.12 Million USD | 77.113% |
| Resverlogix Corp. | -11.74 Million USD | 95.864% |
| Affymax, Inc. | -14.29 Million USD | 96.602% |
| SYBLEU INC | -141.57 Thousand USD | -243.063% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 84.144% |
| argenx SE | -216.02 Million USD | 99.775% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.122% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 139.908% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 67.598% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 228.2% |
| AVAX Technologies, Inc. | -6.11 Million USD | 92.055% |
| Zenith Capital Corp. | -8.6 Million USD | 94.357% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.805% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -2687.888% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 80.148% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -175.915% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 98.775% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 83.208% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 53.582% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 7323.052% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 72.247% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 74.716% |
| BioStem Technologies, Inc. | -7.55 Million USD | 93.57% |
| ONE Bio Corp. | 13.61 Million USD | 103.568% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -168.2% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 76.389% |
| Agentix Corp. | -1.37 Million USD | 64.594% |
| LadRx Corporation | 412.28 Thousand USD | 217.802% |
| Cell Source, Inc. | -4.27 Million USD | 88.633% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -32.258% |
| Regen BioPharma, Inc. | 1.46 Million USD | 133.13% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 48.164% |
| NovAccess Global Inc. | -1.03 Million USD | 53.065% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 105.486% |
| Itoco Inc. | -1.86 Million USD | 74.014% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -27.938% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 56.48% |
| Kadimastem Ltd | -2.62 Million USD | 81.494% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -103.085% |
| CytoDyn Inc. | -18.02 Million USD | 97.306% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -514.557% |
| Mobile Lads Corp. | -2.24 Million USD | 78.329% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -3871.527% |
| Qrons Inc. | -40.08 Thousand USD | -1111.741% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 192.083% |
| Rebus Holdings, Inc. | -951 Thousand USD | 48.93% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 54.268% |
| International Stem Cell Corporation | 202 Thousand USD | 340.435% |
| Bioxytran, Inc. | -3.82 Million USD | 87.286% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -822.641% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 80.272% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 98.646% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -979.284% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 82.262% |
| Neutra Corp. | -181.24 Thousand USD | -167.965% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 97.591% |
| PureTech Health plc | -11.62 Million USD | 95.823% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 97.591% |
| IXICO plc | -707 Thousand USD | 31.304% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 93.68% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 98.995% |
| CSL Limited | 4.73 Billion USD | 100.01% |
| Cellectis S.A. | -92.63 Million USD | 99.476% |